Fig 2: Statistically significant association was observed between S100P immunoreactivity and patient overall survival. (P<0.01) S100P, S100 calcium binding protein P.

Fig 3: Effects of S100P silencing on the expression levels of migration-associated proteins in C666-1 cells. Western blotting was used to analyze the protein expression levels of EGFR, CD44, MMP2 and MMP9 in C666-1 cells that had been transfected with S100P siRNA. The expression levels of these proteins were decreased in the S100P siRNA group compared with the negative control siRNA and untreated control groups. S100P, S100 calcium binding protein P; siRNA, small interfering ribonucleic acid; EGFR, epidermal growth factor receptor; CD44, cluster of differentiation 44; MMP, matrix metalloproteinase; MMP, matrix metalloproteinase.

Fig 4: RAGE protein expression levels were analyzed using western blotting in C666-1 cells that had been transfected with S100P siRNA. RAGE expression was decreased in the S100P siRNA group compared with the negative siRNA control and untreated control groups. RAGE, receptor for advanced glycation end products; S100P, S100 calcium binding protein P.

Fig 5: Hematoxylin and eosin staining in NPC tissues. (A) S100P positive staining in NPC (magnification, ×100). (B) S100P positive staining in NPC (magnification, ×200). (C) S100P negative staining in NPC (magnification, ×100). (D) S100P negative staining in NPC (magnification, ×200). (E) S100P negative staining in benign inflammation (magnification, ×100). (F) S100P negative staining in benign inflammation (magnification, ×200). (G) magnification, ×100; (H) magnification, ×200). NPC, nasopharyngeal carcinoma; S100P, S100 calcium binding protein P.